The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner

Most non-Hodgkin's lymphomas (NHL) initially respond to chemotherapy, but relapse is common and treatment is often limited by chemotherapy-related toxicity. Bortezomib, is a highly selective proteasome inhibitor with anti-NHL activity; it is currently FDA approved for second-line treatment of m...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Shiloh M, Churchill, Eric, McKnight, Hayes, Mahaffey, Christopher M, Ma, Yunpeng, O'Donnell, Robert T, Tuscano, Joseph M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287147/
https://www.ncbi.nlm.nih.gov/pubmed/22128838
http://dx.doi.org/10.1186/1756-8722-4-49

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287147/
https://www.ncbi.nlm.nih.gov/pubmed/22128838
http://dx.doi.org/10.1186/1756-8722-4-49

Ejemplares similares